GURUFOCUS.COM » STOCK LIST » Consumer Cyclical » Manufacturing - Apparel & Accessories » TATA Health International Holdings Ltd (HKSE:01255) » Definitions » Risk Assessment

TATA Health International Holdings (HKSE:01255) Risk Assessment


View and export this data going back to 2013. Start your Free Trial

What is TATA Health International Holdings Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of TATA Health International Holdings is: High Risk: High uncertainty.


Competitive Comparison of TATA Health International Holdings's Risk Assessment

For the Footwear & Accessories subindustry, TATA Health International Holdings's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TATA Health International Holdings's Risk Assessment Distribution in the Manufacturing - Apparel & Accessories Industry

For the Manufacturing - Apparel & Accessories industry and Consumer Cyclical sector, TATA Health International Holdings's Risk Assessment distribution charts can be found below:

* The bar in red indicates where TATA Health International Holdings's Risk Assessment falls into.



TATA Health International Holdings  (HKSE:01255) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.


TATA Health International Holdings Risk Assessment Related Terms

Thank you for viewing the detailed overview of TATA Health International Holdings's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.


TATA Health International Holdings (HKSE:01255) Business Description

Traded in Other Exchanges
N/A
Address
15-33 Kwai Tak Street, Flat F-J, 11th Floor, Block 2, Kwai Tak Industrial Centre, Kwai Chung, New Territories, Hong Kong, HKG
TATA Health International Holdings Ltd is an investment holding company. Through its subsidiaries, the company operates in four segments: Trading of footwear products, Trading of healthcare products, financial services, and Online medical services. The majority of its revenue comes from the Trading of footwear products. Its geographical segments are Hong Kong, Australia, Macau, and Mainland China of which majority of its revenue comes from Hong Kong.

TATA Health International Holdings (HKSE:01255) Headlines

No Headlines